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Abstract
Osteosarcoma (OS) is primary malignant bone tumour with complicated early diagnosis. There are no specific markers currently 
available for predicting the prognosis and chemosensitivity of OS.  In present study we performed transcriptome profiling of single 
patient tumour tissue with RNA-seq technology. We analysed surgically removed sarcoma sample from single 16 years old male 
patient. Transciptome analysis was done with RNA-seq technology, bioinformatics with Lifescope and R Bioconductor. Validation 
experiments were done with quantitative real-time PCR (QRTPCR). After quality and coverage filtering, RNA-seq experiment 
resulted 29,311,899 mapped reads for sarcoma and 22,099,159 mapped reads for normal bone tissue. 65 genes were differentially 
expressed with FDR corrected statistical significance below 0.05. Seven genes were down-regulated and 58 genes were up-regulated 
in sarcoma. The most highly up-regulated gene in sarcoma was adiponectin, ADIPOQ (with adjusted p-value 5.5E-07, log2 fold 
change was 7.9). Many of the genes we found are related to the adipose tissue metabolism (ADIPOQ, PLIN1, FABP4) and to the Wnt 
signalling suppression (WIF1, SOST). We also found novel fusion transcript between the genes LMTK2 and ZSWIM5. LMTK2 is 
lemur tyrosine kinase 2, and it has been shown to be involved in NGF-TrkA signalling. Interestingly, studies support the involvement 
of LMTK2 in development of prostate cancer. ZSWIM5 is zinc finger SWIM domain protein 5 and its function is not known. 
Immunohistochemical analysis confirmed positive staining for adiponectin in osteosarcoma. This paper is a good illustration how 
transcriptome analysis can find new biomarkers and targets for complex diseases.
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Introduction
Osteosarcoma (OS) is the most frequent primary bone tumour 
in children and adolescents [1]. It is malignant mesenchymal 
sarcoma and if left untreated it progresses to local and systemic 
disease. OS is devastating disease with poor early diagnosis and 
a low long-term survival rate despite significant improvements 
in therapy. Although OS is rare disease, its high mortality 
makes its overall contribution to cancer mortality high [2]. 
Occasionally familial involvement in OS has been observed. 
Therefore, genetic susceptibility plays some role in the disease 
development and genetic regulation seems to be important in 
disease progression. P53 has frequently found to be involved 
in OS development and it is suggested as a target for gene 
therapy of sarcoma [3,4]. Wnt signalling pathway is involved 
in the bone formation and also in sarcoma development [5-7]. 
According to current understanding activation of Wnt pathway 
leads to the development of OS [8]. On the other hand, in another 
recent study the inactivation of Wnt signalling in high-grade 
OS biopsies was shown [9]. Activation of Wnt signalling was 
shown to inhibit proliferation of cells and promote osteogenic 
differentiation in osteosarcoma cell lines [9]. Therefore, the 
results on the Wnt signalling involvement in OS development 
are somewhat controversial. Most likely, this is caused by the 
differences in models and methods applied in different studies.
In many cases, new fusion transcripts in malignant samples 
have been described and this reflects genomic complexity of 
the OS [10]. OS is genomically unstable tumour what makes its 
chemical and biological therapy complicated [11]. This cancer 
is very aggressive and develops distant metastases in 45% 
even with the intensive neoadjuvant treatment with multiple 
chemotherapeutic drugs [12]. Survival of patients has increased 
only slightly and no other significant improvement has been 
made since decades [13-15]. Therefore, new drugs are seriously 
needed for OS. Better understanding of the OS biology and 
genomics can give us new information and potential targets 
for drug development.
In present study we performed transcriptome profiling 
of single patient tumour tissue with RNA-seq technology. 
We compared tumorous tissue with patient’s own normal 
bone tissue in order to find specific profile in transcriptome 
characteristic for the sarcoma. RNA-seq is most comprehensive 
analytical tool for transcriptome profiling and in addition to 
conventional gene expression profiling it allows finding of 
transcriptional aberrations, fusions, what can be potentially 




important for the tumorigenesis. Although this study is 
exploratory and its results need to be confirmed by further 
studies, we were able to describe the genetic network behind 
OS and new potential biomarker.
Methods
Subject
Patient, 16 years old male, became ill with complaints of 
pain in left knee area. History of trauma was missing and 
GP administered painkillers and vitamins. After 6 months 
he returned to GP with complaints of pain, swelling and 
dysfunction in left distal femur and knee area. The swelling 
line observed in left femoral distal region, the area was thicker 
and painful during the touch. No changes in skin color were 
detected. The X-ray investigation showed additional shading 
and structural change in distal part of left femur. For detailed 
investigation the MRI was performed and as a result malignant 
process was suspected. Patient was hospitalized and bone 
biopsy was taken for histological investigation. The diagnosis 
of osteosarcoma was confirmed.
Chemotherapy for osteosarcoma started by SSG XIV 
treatment protocol. After 3 month of chemotherapy surgical 
removal of tumor (distal part of femoral bone with knee 
joint) and replacement of knee and lower part of femur with 
megaprosthesis was performed. Materials for this study were 
collected from surgically removed tissue.
RNA extraction and RNA-seq
RNA was extracted by using the Trizol combined with columns 
(RNeasy Mini kit, Qiagen Sciences, Maryland, USA). Up to 
100mg of tissue was used for extractions. In brief, mortar was 
washed with DEPC water (about 20 min) and bone sample was 
placed into mortar. Liquid nitrogen was added three times. 
Each time the nitrogen was allowed to boil off and finally, 
bone was grinded into a powder. Trizol was added to the 
homogenized bone tissue and the mix was transferred into a 
polypropylene tube, followed by centrifugation. Supernatant 
was transferred into a new tube and RNA extraction with 
RNeasy Mini kit was followed.
The quality of total RNA was evaluated with Agilent 2100 
Bioanalyzer and RNA 6000 Nano kit (Agilent Technologies Inc., 
California, USA). The average RIN number for the samples was 
at least 7.50 ng of total RNA was amplified by applying Ovation 
RNA-Seq System V2 (NuGen, Emeryville, CA, USA) after which 
the resulting cDNAs were pooled in equal amount and the 
pool was used to prepare the DNA fragment library with SOLiD 
System chemistry (Life Technologies Corp., Carlsbad, CA, USA). 
Sequencing was performed using SOLiD 5500xl platform and 
paired-end DNA sequencing chemistry (Life Technologies 
Corp., Carlsbad, CA, USA). 75 bp from forward and 35 bp from 
reverse direction was sequenced and altogether at least 40 
million reads per sample was received, which is sufficient for 
the evaluation of expression pattern of the transcriptome.
Bioinformatics analysis
For bioinformatics analysis Lifescope software was used. This 
is proprietary software developed by Life Technologies and 
allows complete analysis of sequencing data from mapping 
to the annotation and structural analysis. Briefly, raw data 
were mapped to reference genome and list of gene counts 
was generated. In addition, exon junctions and gene fusions 
were detected to find alternative transcriptional modifications. 
For statistical analysis DeSeq package for R was used [16]. 
DeSeq is a package what is specifically developed for RNA-seq 
or other counts data. The package DeSeq provides methods 
to test for differential expression by use the negative binomial 
distribution and a shrinkage estimator for the distribution’s 
variance [16]. DeSeq also allows performing analysis of the 
data without replicates. In such case, the dispersion is estimated 
from comparing their counts across conditions as replacement 
for a proper estimate of the variance across the replicates. 
Package performs sample comparison and also adjusts P-value 
to overcome multiple testing problem. DeSeq package uses 
Benjamini-Hochberg procedure, which controls for false 
discovery rate (FDR) [17].
Ingenuity pathway analysis (IPA, Ingenuity Systems, http://
www.ingenuity.com) software was used to functionally 
annotate RNA-seq results.
Quantitative real-time PCR
For gene-expression analysis first strand cDNA was synthesized 
by using random primers and SuperScriptTM III Reverse 
Transcriptase (Invitrogen, USA). Gene expression levels of 
the selected 11 genes were analyzed by applying TaqMan 
Assay-On-Demand (FAM-labeled MGB-probe) gene expression 
assay mix (20x, Applied Biosystems, Foster City, CA, USA) 
and TaqMan Universal PCR Master Mix (Applied Biosystems, 
Foster City, CA, USA). For quantitative real-time PCR (qRT-PCR) 
analysis the ABI PRISM 7900HT Fast Real-Time PCR System 
equipment (PE Applied Biosystems, USA) and the ABI 
PRISM 7900 SDS 2.2.2 Software were used. Every reaction 
was made in four replicates to minimize possible errors. All 
reactions were performed in a final volume of 10 μl, using 
50-100 ng of cDNA. Data is presented as 2-ΔCT calculated in 
relation to the HPRT1. For HPRT1 analysis, primer for exon 6 
(5’-GACTTTGCTTTCCTTGGTCAGG-3’) and primer for exon 7 
(5’-AGTCTGGCTTATATCCAACACTTCG-3’) and VIC-labeled MGB 
probe was used. All the assays and respective genes used in 
RT-PCR are listed in (Table 1).
Immunohistochemical staining
We used Anti-Adiponectin antibody ab22554 [19F1] from 
ABCAM and Ventana BenchMark ULTRA slide-staining system. 
Slides were baked (62oC, 12 minutes) and deparaffinized (65oC), 
antigen was retrieved with the ULTRA CC1 64 min (95oC) and 
then blocked with UV inhibitor (3% H202, 4 minutes). Slides 
were incubated with primary antibody (dilution 1:100) for 
32 minutes (37oC) and staining was detected with UltraView 




Universal DAB Detection Kit. 
Results
Identification of differentially expressed genes between 
normal bone and osteosarcoma
After quality and coverage filtering, RNA-seq experiment 
yielded 29,311,899 mapped reads for sarcoma sample and 
22,099,159 mapped reads for normal bone tissue. We had 
annotated 24,922 genes and 21,825 genes were expressed 
in one or another sample. Statistical analysis with DeSeq 
identified that 65 genes were differentially expressed with 
multiple testing corrected statistical significance below 0.05 
(Table 2). 7 genes were up-regulated in normal tissue and 58 
genes were up-regulated in sarcoma. The most highly up-
regulated gene by statistical significance was adiponectin, 
ADIPOQ (with adjusted p-value 5.5E-07). Adiponectin was almost 
the most activated gene by fold change, log2 fold change 
was 7.9, what is about 250 times over-expressed compared 
to control tissue. By fold change the most up-regulated gene 
was triadin, TRDN. TRDN has log2 fold change 8.2 (Table 2).
We made two observations by looking the list of the 
differentially expressed genes. First, very few genes were over-
expressed in the healthy bone compared with sarcoma. This 
means, sarcoma produces very actively (in high levels) large 
number of genes. And second, many of the genes we found 
are related to the adipose tissue metabolism (adiponectin, 
perilipin 1, fatty acid binding protein 4). We also found typical 
genes for bone tissue (e.g. Wnt inhibitory factor 1, WIF1 and 
sclerostin, SOST), but quite many of the genes are characteristic 
for adipose tissue. There are also genes participating in 
immune response. WIF1 is a gene what is involved in different 
malignancies and it regulates cell cycle [18,19]. In recent study 
its involvement in osteosarcoma was shown [20].
In addition to the counts data, RNAseq enables detection 
of potential fusion transcripts. In sarcoma sample, we found 
novel fusion transcript between the genes LMTK2 and 
ZSWIM5 (Table 3, Figure 1). LMTK2 is lemur tyrosine kinase 2, 
and it has been shown to be involved in NGF-TrkA signalling 
[21]. Interestingly, several studies support the involvement 
of LMTK2 in development of prostate cancer [22-24]. ZSWIM5 
is zinc finger SWIM domain protein 5 and its function is not 
known very well.
Confirmation of differentially expressed gene with 
quantitative RT-PCR 
We tested 11 genes with most significant differences from 
RNAseq data. Quantitative real-time PCR confirmed differences 
with almost all tested 11 genes (Figure 2). Thus, in case of PANX3 
we found significant down-regulation in sarcoma samples and 
all other genes were up-regulated in sarcoma. Only in case 
of TRDN we didn’t find difference between normal bone and 
sarcoma sample. This is peculiar, as the difference based in 
RNAseq analysis was very large. As RNAseq gives information 
also based on exons, we checked the situation with TRDN. 
Indeed, we found that in sarcoma sample for exon 1 in TRDN 
genes there were 361 reads (RPKM 16.96). There were reads 
also matching to other exons (RPKMs around 3…10). In normal 
bone sample, no reads were mapped to any exons of TRDN 
gene. As the real-time PCR assay for TRDN (Hs00952568_m1) 
detects only junction between 2 and 3 exons, this may explain 
the discrepancy between RNAseq and RT-PCR data. Therefore, 
in case of TRDN we have alterative splicing between test 
samples and this generates some confusion. TRDN is known 
to have several different transcripts and different alternative 
forms exist [25]. However, as the function of TRDN is not known, 
this finding should be taken cautiously.
All genes with statistically significant gene expression 
levels were used for clustered analysis. This analysis revealed 
clear differences in gene expression profiles in analysed two 
samples (sarcoma and normal bone, heatmap in (Figure 3). 
This indicates correct sample preparation and grouping.
Functional annotation of the RNA-seq data
Functional annotation of RNAseq data was performed with 
the IPA system. We filtered data and for log2FC values cutoff 
4 was used. Most significantly enriched network was network 
called “Hematological Disease, Metabolic Disease, Endocrine 
System Development and Function” (Figure 4). This means 
that the genes with the largest differences are related to the 
oncogenesis and endocrine regulation.
Confirmation of adiponectin expression with immuno-
histochemistry 
We analysed histological sample of osteosarcoma with 
adiponectin antibody and found strong staining in the osteoid, 
matrix and endothelial cells (Figure 5). Therefore, adiponectin 
expression in osteosarcoma was also confirmed in protein level. 
Discussion













Table 1. The list of Taqman real-time PCR assays 
and the genes analysed to confirm RNA-seq data.
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Gene ID Normal Sarcoma FC log2FC pval padj Gene name
ADIPOQ 7.64 1819.74 238.27 7.9 2.77E-11 5.59E-07 adiponectin
WIF1 15.27 2099.10 137.42 7.1 2.57E-10 2.59E-06 WNT inhibitory factor 1
TRDN 1.09 330.39 302.82 8.24 1.39E-08 9.31E-05 triadin
LOC255167 6.55 527.59 80.59 6.33 5.69E-08 0.0003 --
PLIN1 5.46 443.69 81.33 6.35 9.23E-08 0.0004 perilipin 1
CHI3L1 9.82 595.91 60.69 5.92 1.26E-07 0.0004 chitinase 3-like 1 (cartilage glycoprotein-39)
ADH1B 1.09 227.47 208.48 7.7 1.63E-07 0.0005 alcohol dehydrogenase 1B (class I). beta polypeptide
PANX3 6651.11 221.41 0.03 -4.91 5.44E-07 0.0003 pannexin 3
SOST 168.02 5307.86 31.59 4.98 4.5E-07 0.0001 sclerostin
CHI3L2 36.01 1254.1 34.83 5.12 5.46E-07 0.0001 chitinase 3-like 2
IGLL5 7.64 420.34 55.04 5.78 4.52E-07 0.0001 immunoglobulin lambda-like polypeptide 5
IFI27 98.2 2797.07 28.48 4.83 9.88E-07 0.0017 interferon. alpha-inducible protein 27
FABP4 20.73 691.05 33.34 5.06 1.38E-06 0.0021 fatty acid binding protein 4. adipocyte
MMP3 0.0 130.60 Inf Inf 1.49E-06 0.0021 matrix metallopeptidase 3
DNASE1L3 4.36 252.55 57.87 5.85 1.84E-06 0.0025 deoxyribonuclease I-like 3
GZMA 0.0 122.82 Inf Inf 1.98E-06 0.0025 granzyme A (granzyme 1)
IGJ 13.09 452.34 34.55 5.11 2.49E-06 0.0029 immunoglobulin J polypeptide
CHRDL1 16.37 505.96 30.92 4.95 2.9E-06 0.0033 chordin-like 1
WDR72 21.82 630.51 28.89 4.85 3.11E-06 0.0033 WD repeat domain 72
PTX3 75.28 1628.6 21.63 4.44 5.75E-06 0.0058 pentraxin 3, long
RGS18 2.18 151.36 69.36 6.12 7.97E-06 0.0074 regulator of G-protein signaling 18
GFRA1 14.18 394.39 27.81 4.8 8.12E-06 0.0074 GDNF family receptor alpha 1
PRG4 952.5 17119.72 17.97 4.17 1.02E-05 0.0086 proteoglycan 4
C7 3.27 171.25 52.32 5.71 1.02E-05 0.0086 complement component 7
RSAD2 55.64 1086.31 19.52 4.29 1.25E-05 0.0097 radical S-adenosyl methionine domain containing 2
EPYC 14.18 368.45 25.98 4.7 1.24E-05 0.0097 epiphycan
HBB 53.46 1030.09 19.27 4.27 1.35E-05 0.0101 hemoglobin, beta
F13A1 180.03 2990.80 16.61 4.05 1.94E-05 0.0132 coagulation factor XIII. A1 polypeptide
CRTAC1 126.56 2144.07 16.94 4.08 1.92E-05 0.0132 cartilage acidic protein 1
Table 2. Differentially expressed genes between normal bone and osteosarcoma. Genes are ranked based on the adjusted 
p-values.
E1 E1-reference E2 E2-reference E1-size E2-size E1-readcount E2-readcount E1-RPKM E2-RPKM
LMTK2-11 Chr7 ZSWIM5-2 Chr1 2959 357 157 8 5.99 2.53
Table 3. Description of the fusion transcript we found in osteosarcoma sample during RNAseq analysis.
tissue, osteosarcoma expresses quite many specific transcripts. 
These transcripts can be taken as potential biomarkers or new 
drug targets for the osteosarcoma. The genes found in our 
study, seem to have involvement in development of OS or in 
other cancers. However, more information about their roles in 
OS development is needed. As this study is also exploratory 
additional studies should be performed in order to test their 
validity. We try to analyse the list of genes in the light of more 
recent findings.
Adiponectin (ADIPOQ) seems to be good biomarker for 
osteosarcoma studies. While ADIPOQ has not been related 
to OS in earlier studies, there are some studies where the 
role of ADIPOQ in cancer development has been addressed. 
Namely, one very recent meta-study revealed the association 
of ADIPOQ with risk of cancer development [26]. In addition, 
adiponectin is able to induce motility of prostate cancer 
and chondrosarcoma cells [27,28]. Moreover, adiponectin 
is closely associated with bone remodelling and bone 
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Figure 1. Circos plot illustrating the fusion of two transcripts and their original location 
in the human genome.
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Figure 3. Heatmap illustrates the clustering of genes with significantly differential 
expression between the samples.
pathologies [29,30]. Serum adiponectin levels have shown 
to be inversely associated with bone mineral density [31]. 
Our immunohistological analysis confirmed high expression 
of adiponectin in osteoid. Therefore, adiponectin could be 
useful marker for OS patients as well.
WIF1 is a gene with very clear involvement in oncogenesis. 
Generally, WIF1 is silenced by epigenetic inactivation during 
cancer development, but this is not limited to osteosarcoma 
[19,20]. WIF1 is inhibitor of Wnt signalling and therefore it 
is involved in development and remodelling of different 
tissues [32]. What is somewhat controversial is our finding 
of increased expression of WIF1 in OS patients because it 
supposed to be silenced or down-regulated in cancer samples 
[20]. In our study we clearly detected up-regulation of WIF1 
in sarcoma patient and this may indicate suppression of Wnt 
signalling in our sample. This hypothesis needs to get more 
confirmation with additional studies. On the other hand, 
increased sclerostin (SOST) expression supports the idea 
that Wnt signalling is suppressed in the patients in our study. 
Namely, increased SOST is related to the inhibition of Wnt 
signalling [33]. Therefore, increased SOST level fits very well 
with increased WIF1 what decreases activity of Wnt signalling.
SOST seems to be antagonist for Wnt signalling and 
therefore, up-regulation of WIF1 and SOST seems to fit with 
each other [33-35]. This means that our finding generates 
functional network describing the restructuring activity in 
the bone during tumorigenesis. Down-regulation of Wnt 
signalling pathway in osteosarcoma is also described in some 
earlier studies. Earlier studies have similarly found clear down-
regulation of Wnt signalling in 25 high-grade prechemotherapy 
biopsies [36]. In many studies the comparisons are not made 
between healthy bone and osteosarcoma, therefore not all 
published gene expression-profiling studies are comparable 
with ours [37,38]. Therefore, some controversies exist about 
the involvement of Wnt signalling pathway in OS development.
Interestingly, in OS sample we found quite many genes 
related to the adipocyte functioning. Perilipin 1 or PLIN1 is 
one example. This gene produces protein what coats the 
lipid storage droplets in adipocytes and protects them until 
they can be broken down by lipase [39,40]. Similarly, FABP4 is 
fatty acid binding protein 4 and is described to be specific for 
adipocytes [41]. Two explanations are possible. This finding 
can reflect that during tumorigenesis osteoblasts differentiate 
to adipocytes. On the other hand, this can be also normal 
phenotype of osteosarcoma cells. According to literature, 
both variants have been described. Ultrastructural analysis 
of osteosarcoma cell described lipid droplets in all types of 
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Figure 4. Ingenuity Pathway Analysis software was used for functional 
analysis to define genetic networks related to the osteosarcoma development. 
Functional analysis identified “Hematological Disease, Metabolic Disease, 
Endocrine System Development and Function” network to be activated in 
sarcoma sample. Genes with green colour are down regulated and genes in red 
colour are up regulated. This graph illustrates functional interactions between 
differentially expressed genes in sarcoma sample.
Figure 5. Photomicrograph of adiponectin immunohistochemical staining 
illustrates positive staining in sarcoma sample. (400 x magnification)
8
doi: 10.7243/2052-7993-1-3
Märtson et al. Genomics Discovery 2013, 
http://www.hoajonline.com/journals/pdf/2052-7993-1-3.pdf
adipocytes by inhibition of gap-junctional communication or 
by hormonal stimulation [43,44]. Taken together, adipocyte 
specific transcripts in osteosarcoma sample are quite common 
and this finding is in accordance of the literature.
Our study has some very clear limitations. For instance, 
sample size was very small in our study. Analysis based 
on single sample is very exploratory and does not provide 
conclusive evidence. We are fully aware, that the results 
presented here, should be verified in independent, large 
sample.
Conclusions
In conclusion, our whole transcriptome profiling of 
osteosarcoma identified down regulation of Wnt signalling 
pathway and adiponectin as potential biomarker for 
osteosarcoma relevant for the tumour progression. These 
changes can potentially explain molecular nature of the 
osteosarcoma.
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